Shares of Sienna Biopharmaceuticals stock opened at $5.40 on Monday. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.67. The firm has a market cap of $122.61 million, a price-to-earnings ratio of -1.04 and a beta of 1.57. Sienna Biopharmaceuticals has a 12 month low of $5.06 and a 12 month high of $25.71.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.03). Sell-side analysts anticipate that Sienna Biopharmaceuticals will post -2.95 EPS for the current year.
Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Sienna Biopharmaceuticals by 12,865.9% in the 1st quarter. Royal Bank of Canada now owns 5,705 shares of the company’s stock worth $107,000 after purchasing an additional 5,661 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth about $182,000. Neuburgh Advisers LLC raised its position in shares of Sienna Biopharmaceuticals by 75.6% in the 2nd quarter. Neuburgh Advisers LLC now owns 12,896 shares of the company’s stock worth $196,000 after purchasing an additional 5,552 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth about $200,000. Finally, Bridgeway Capital Management Inc. purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth about $225,000. 48.18% of the stock is owned by institutional investors and hedge funds.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.